Each year, two out of three cancer patients undergo radiation therapy, which equates to 1.5M patients in Europe and 2M in the US. However, scientific evidence demonstrates a direct link between radiation therapy and several serious delayed effects. This is because the tolerance of patients to radiation varies significantly and radiotherapy affects indiscriminately both healthy and cancer cells, damaging also active working tissues and organs around the tumour. Hence there is an unmet clinical need to tailor treatments to each patient’s unique physiological characteristics.
NovaTests are the first predictive radio-sensitivity tests for cancer treatment. By analysing a simple blood sample, within a week, the test can determine with an accuracy of over 90% not only whether a patient is sensitive or not to radiation but also how sensitive they are. NovaTests allow for more efficient treatments and improved quality of life for cancer survivors, not only during radiation treatments but for the rest of their lives. The first test, the NovaGray Breast® is aimed at measuring radiosensitivity for breast cancer patients.